New AntiVirals 

for Infections 

with Pandemic 

Potential

For infectious disease management and control, vaccines are considered golden countermeasures 
but are not the most adequate tool for mitigating 
the early effects of an outbreak.

Taking the recent COVID-19 pandemic as an example, access to broadly applicable therapeutic antivirals would have had a major impact, decreasing the human toll of the disease, and alleviating the burden carried by health care systems. It is urgent to focus resources and efforts on the development of broad spectrum antiviral drugs against unknown pathogens.

The New AntiVirals for Infections with Pandemic Potential (NAVIPP) consortium aims to strengthen the EU’s readiness and response capacity to viral threats by assembling an international R&D platform for antiviral drug development against pandemic prone pathogens.

navipp by
numbers

0

partners

0

countries

0

years EU-funded
project

0

millions €

NEWS

  • NAVIPP project poised to contribute to WHO’s new R&D Blueprint for Epidemics

    WHO’s New Pathogens Prioritization Framework In 2015, the World Health Organization (WHO), at the request of almost 200 member states, developed its first Research & Development (R&D) Blueprint for Action to Prevent Epidemics focusing on a number of specific severe infectious diseases for which no medical countermeasures (MCMs) were available. Launched for the first time…

  • NAVIPP Kick-Off Meeting on March 20-21, 2024 in Paris

    The NAVIPP Kick-Off Meeting aimed to set the stage for the project’s strategic and operational framework, fostering collaboration among partners to address epidemic and pandemic viral threats through research and innovation. NAVIPP represents a collaborative effort among esteemed international research institutions, pharmaceutical entities, and public health organizations. At its core, NAVIPP seeks to establish an…